Sysmex Corporation (TYO:6869)

Market Cap	960.06B
Revenue (ttm)	498.69B
Net Income (ttm)	46.69B
Shares Out	623.62M
EPS (ttm)	74.85
PE Ratio	20.57
Forward PE	18.32
Dividend	36.00 (2.32%)
Ex-Dividend Date	Mar 30, 2026

Volume	2,682,300
Average Volume	2,769,050
Open	1,567.50
Previous Close	1,539.50
Day's Range	1,548.50 - 1,572.00
52-Week Range	1,435.00 - 3,063.00
Beta	0.69
RSI	51.62
Earnings Date	Feb 12, 2026

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1968
• Employees: 10,533
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 6869

Financial Performance

In 2024, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.